Previous animal studies suggest that the therapeutic effects of MSCs on AD-related cognitive impairment involve the reduction of Aβ accumulation, tau accumulation, and neuroinflammation, and also increased neurogenesis [13–16, 21–23]. The gene discussed is MAPT; the disease is Cognitive impairment.